Clinical Trial Update: Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating carrelizumab in combination with chemotherapy as adjuvant therapy for Esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Esophagus Cancer

Drugs mentioned

• Carrelizumab (camrelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophagus Cancer | Phase 2 | Status: UNKNOWN